Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Maximizing Benefits, Minimizing Risk.
Authors
Clarke, Noel WAffiliation
The Christie and Salford Royal Hospitals, Manchester University, Manchester, United Kingdom.Issue Date
2010-09-26
Metadata
Show full item recordCitation
Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Maximizing Benefits, Minimizing Risk. 2010: Eur UrolJournal
European UrologyDOI
10.1016/j.eururo.2010.09.027PubMed ID
20934244Type
ArticleLanguage
enISSN
1873-7560ae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2010.09.027
Scopus Count
Related articles
- Integrating surgery with targeted therapies for renal cell carcinoma: current evidence and ongoing trials.
- Authors: Bex A, Jonasch E, Kirkali Z, Mejean A, Mulders P, Oudard S, Patard JJ, Powles T, van Poppel H, Wood CG
- Issue date: 2010 Dec
- Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma.
- Authors: Chapin BF, Delacroix SE Jr, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG
- Issue date: 2011 Nov
- The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.
- Authors: Powles T, Blank C, Chowdhury S, Horenblas S, Peters J, Shamash J, Sarwar N, Boleti E, Sahdev A, O'Brien T, Berney D, Beltran L, Nathan P, Haanen J, Bex A
- Issue date: 2011 Sep
- High-dose interleukin-2 in metastatic renal cell carcinoma.
- Authors: Fernández-Rodríguez R, de Argumedo GL, Mañé JM, Muñoz A, Ferreiro J, Fuente N, López-Vivanco G
- Issue date: 2005 Sep 20
- Neoadjuvant Targeted Molecular Therapy Before Renal Surgery.
- Authors: Dey S, Peabody HN, Noyes SL, Lane BR
- Issue date: 2017 May